EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Sponsor

Roswell Park Cancer Institute (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06011772

Collaborator

(none)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in combination with standard therapies used in the treatment of advanced colorectal cancer.

Condition or Disease	Intervention/Treatment	Phase
Colo-rectal Cancer	Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Drug: Leucovorin Drug: Oxaliplatin Drug: Fluorouracil Biological: Bevacizumab Drug: Irinotecan Biological: Cetuximab Procedure: Metastasectomy Procedure: Biospecimen collection	Early Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

42 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Anticipated Study Start Date :

Oct 2, 2023

Anticipated Primary Completion Date :

Oct 2, 2025

Anticipated Study Completion Date :

Oct 2, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort A LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy consisting of leucovorin IV, oxaliplatin IV over 2 hours, and fluorouracil IV and bevacizumab IV over 10 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial.	Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Given IM Other Names: Cimavax CIMAvax EGF Epidermal Growth Factor (EGF) Vaccine Drug: Leucovorin Given IV Drug: Oxaliplatin Given IV Drug: Fluorouracil Given IV Biological: Bevacizumab Given IV
Experimental: Cohort B1 LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive FOLFIRI consisting of irinotecan IV, leucovorin IV over 90 minutes, and fluorouracil IV and cetuximab IV over 120 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial.	Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Given IM Other Names: Cimavax CIMAvax EGF Epidermal Growth Factor (EGF) Vaccine Drug: Leucovorin Given IV Drug: Fluorouracil Given IV Drug: Irinotecan Given IV Biological: Cetuximab Given IV Procedure: Biospecimen collection Undergo collection of blood samples
Experimental: Cohort B2 LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy and cetuximab IV over 120 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial	Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Given IM Other Names: Cimavax CIMAvax EGF Epidermal Growth Factor (EGF) Vaccine Drug: Oxaliplatin Given IV Drug: Fluorouracil Given IV Biological: Cetuximab Given IV Procedure: Biospecimen collection Undergo collection of blood samples
Experimental: Cohort C Description LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 and cetuximab, FOLFOX6 and bevacizumab, or mFOLFOX6 per investigators preference. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo metastasectomy 4-8 weeks after first maintenance phase dose. Patients undergo collection of blood samples throughout the trial.	Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Given IM Other Names: Cimavax CIMAvax EGF Epidermal Growth Factor (EGF) Vaccine Drug: Leucovorin Given IV Biological: Bevacizumab Given IV Biological: Cetuximab Given IV Procedure: Metastasectomy Undergo metastasectomy Procedure: Biospecimen collection Undergo collection of blood samples

Outcome Measures

Primary Outcome Measures

Immunogencity of vaccine [up to 60 days after last dose]
Percentage of patients with antibody titers greater than or equal to 1:4000 using a 90% confidence interval obtained by Jeffery's prior method

Secondary Outcome Measures

Progression free survival [time from treatment until disease progression, death or last follow up assesed up to 2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed metastatic adenocarcinoma of colon or rectum that cannot be removed by surgery without prior systemic therapy for advanced disease (prior adjuvant chemotherapy completed >12 months from diagnosis of metastatic or advanced disease is allowed) for cohorts A and C and with one prior line of therapy but no more than 2 prior lines of therapy for advanced disease (prior adjuvant chemotherapy completed <12 months from diagnosis of metastatic or advanced disease is considered one line of therapy).
Cohort A: May have received 1 cycle of mFOLFOX6± Bevacizumab pending results of RAS and BRAF. If results determine patient is eligible, the patient will be enrolled and will received the addition of CIMAvax + Bevacizumab in their second cycle.
Cohort B: Patients with RAS- and BRAF wild-type metastatic CRC who have received at least one but no more than 2 prior therapies for advanced disease
Cohort C: Patients with RAS- and BRAF wild-type metastatic CRC who have not received prior therapy for advanced disease and are candidates for liver metastasectomy (one cycle of standard therapy with mFOLFOX6 with or without appropriate biologic agent is allowed)
KRAS/NRAS/BRAF (V600) wild-type.
Have an ECOG Performance Status of 0 1. Refer to Appendix A.
Patients must have adequate organ and marrow function as defined below:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelets ≥ 100 x 109/L
Hemoglobin ≥ 8 g/dL
Creatinine clearance> 60 mL/min (Cockcroft-Gault Equation)
ALT and AST ≤ 3 x ULN (ALT and AST ≤ 5 x ULN is acceptable if liver metastases are present
Total bilirubin ≤ 1.5x ULN. For patients with well documented Gilbert's syndrome, total bilirubin ≤ 3x ULN with direct bilirubin within normal range
Have measurable disease per RECIST 1.1 criteria present.
Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Participant agrees to provide tumor biopsy tissue while on study (cohort A and B) or allow tissue to be taken during surgery (cohort C)

Exclusion Criteria:

Toxicity ≥Grade 2 from prior chemotherapy.
Other cancer requiring active treatment.
Prior exposure to anti-EGFR monoclonal antibody (i.e. cetuximab or panitumumab) for colorectal cancer treatment.
Had major surgery within 4 weeks prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery.
Has known immunosuppressive disease (e.g. HIV, AIDS or other immune depressing disease). Testing is not mandatory.
Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
Active, clinically serious infections or other serious uncontrolled medical conditions or psychiatric illness/social situations that would limit compliance with study requirements.
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:
Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease
History of documented congestive heart failure (New York Heart Association functional classification III or IV) within 6 months prior to baseline
Uncontrolled hypertension (SBP>160/DBP>100 despite medical intervention).
History of myocarditis of any etiology
History of ventricular arrhythmias
Active major or clinically significant bleeding based on the International Society on Thrombosis and Hemostasis definition.
Pregnant or nursing female participants.